Recurrence. A Medical Emergency is considered to have ended when medical evidence indicates that the Insured Person is able to return to his or her province or territory of residence. No benefits will be paid in connection with the condition that caused a Medical Emergency if they are incurred after that time.
Recurrence. An employee who suffers a recurrence of disability with one hundred eighty (180) days of the employee’s return to work will become eligible for the remaining portion of benefit according to the salary continuance schedule, without serving forty (40) hour waiting period, provided:
a. The recurrence occurs within 180 days of the employee’s return to work; an
b. The recurrence is due to the same cause; or
c. The recurrence is due to a related cause. A recurrence which occurs more than one hundred eighty (180) days after the initial return to work will be treated as a new illness, injury or disability.
Recurrence. If the Customer’s computer problem reoccurs subsequent to a service by C2S, or another problem occurs, this will be considered a separate issue, and if service is requested, the Customer will be charged Fees.
Recurrence. Each Party shall use all reasonable efforts to prevent a recurrence of any such unauthorized possession, use or knowledge of the other Party’s Confidential Information.
Recurrence does the author use the same passage elsewhere and how regularly?
Recurrence. The deformity the existed prior to surgery may recur. This may necessitate another surgical procedure.
Recurrence. In total 28 patients (23.0%) ended treatment due to recurrence, 15 of the patients were treated with nivolumab, 12 with pembrolizumab and 1 with dabrafenib plus trametinib 6 (Figure 6.3). The recurrence probability at 1 year was 70.3% (95% CI: 58.1–85.0) for nivolumab, 72.4% (95% CI: 60–87.3) for pembrolizumab, and 83.0% (95% CI: 67.1–1) for dabrafenib plus trametinib (Figure 6.4). The No median RFS was reached for any of these treatments within the maximum follow-up period of 13 months.
Recurrence. A disability for which the elimination period does not apply. To be considered a recurrence, a disability period must meet all the following conditions: • It follows an initial period of total disability for which the elimination period has been completed and benefits have been paid by the Insurer; • The new period of total disability is of indeterminate duration and arises from the same or a related cause; • This period is separated from the initial period of total disability by your return to work for a period of less than 30 consecutive days. However, no payment is made for the period during which you returned to your employment between the periods of total disability.
Recurrence. In the event of a recurrence, as detailed above, the deputy sheriff must detail which injury or sickness gave rise to the recurrence and provides the date of the initial injury or illness, in addition, the deputy sheriff must provide any verifying medical report detailing the recurrence. In the event further medical verification is deemed necessary, the deputy sheriff will submit to medical examination as directed by the Sheriff or his designee and as detailed in this procedure, including those detailed in Sections 4 and 5, below.
Recurrence. Recurrence can develop within the eye in previously treated tumours, and regular follow-up examinations are essential. Patients with germ-line mutations are at increased risk of developing secondary malignancies such as pinealblastoma (trilateral retinoblastoma) ectopic intracranial retinoblastoma, and osteogenic or soft tissue sarcomas, melanoma and bladder cancer. The cumulative risk of second cancers has been reported between 20 to 48% over 50 years in various studies. This risk is increased with radiation exposure. The role of long term screening of retinoblastoma survivors is not clearly defined in the literature. Patient education and health awareness play a key role in minimising delay in diagnosis and treatment of second malignancies in these patients. The UHBristol Aftercare MDT picks up long term follow up of patients from the diagnostic and treatment MDTs when they are at least 5 years from first diagnosis and 3 years since completion of last therapy for their primary or any subsequent cancer. The MDT covers both children’s and TYA cancer network for patients who cancers are diagnosed between birth and their 25th birthday. The MDT acts on behalf of the South West Children’s Cancer Network. This document outlines the purpose and organisation of the Aftercare MDT, the structure and the scope of the services offered by the MDT. This document has been written in accordance with national guidelines, and aims to encourage best practice in the management of patients with late effects or ongoing risks related to their treatment for cancer or related diagnoses in childhood or young adulthood. This policy is reviewed on a yearly basis at the operational policy meeting. Given the rarity of paediatric malignancy, and the highly extended nature of the South West region, there is a strong emphasis of operation as a Network, with a well developed shared care system. Late Effects patients are reviewed at the centrally hosted Aftercare MDT. The MDT receives referrals from the following hospitals. • Bristol Royal Hospital for Children • Frenchay Hospital • Royal United Hospital NHS Trust • Gloucester Royal Hospital NHS Foundation Trust • Taunton and Somerset NHS Foundation Trust • Yeovil District Hospital NHS Foundation Trust • Royal Devon and Exeter NHS Foundation Trust • North Devon District Hospital, NHS Trust • Plymouth Hospital NHS Trust • Royal Cornwall Hospital Foundation Trust There is no consistent definition of the terms ‘survivor’, ‘late effects’ or ‘l...
